6CM
OKUR

683 Capital Management’s OnKure Therapeutics OKUR Stock Holding History

683 Capital Management’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-43,371
Closed -$373K – 249
2024
Q4 		$373K Buy
+43,371
New +$657K 0.02% 168

Other funds holding OKUR

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

683 Capital Management's OKUR Position: Q1 2025 in Review

683 Capital Management sold out of OnKure Therapeutics (OKUR) in Q1 2025, closing a stake of 43,371 shares — an estimated $373K sold.

683 Capital Management first reported a position in OKUR in Q4 2024 and held it in 1 quarter. The position peaked at $373K in Q4 2024. 47 funds tracked by Wall St. Rank hold OKUR as of Q1 2025.

  • 683 Capital Management reported no remaining OnKure Therapeutics position as of Q1 2025 after selling out during the quarter.
  • 683 Capital Management sold 43,371 OnKure Therapeutics shares in Q1 2025, an estimated $373K.
  • 683 Capital Management first reported a position in OnKure Therapeutics in Q4 2024 and held it in 1 quarter.
  • 683 Capital Management's OnKure Therapeutics position peaked at $373K in Q4 2024.
  • 47 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q1 2025.

Based on 683 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.